Invitae (NYSE:NVTA) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

NYSE:NVTA opened at $0.00 on Tuesday. The firm’s fifty day moving average is $0.01 and its 200-day moving average is $0.35. Invitae has a 52 week low of $0.02 and a 52 week high of $0.02. The firm has a market cap of $267,010.00, a P/E ratio of 0.00 and a beta of 1.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vestmark Advisory Solutions Inc. bought a new position in Invitae during the fourth quarter worth $526,000. Prosperity Wealth Management Inc. bought a new position in Invitae during the fourth quarter worth $144,000. Bourne Lent Asset Management Inc. boosted its stake in Invitae by 53.3% during the fourth quarter. Bourne Lent Asset Management Inc. now owns 574,600 shares of the medical research company’s stock worth $360,000 after acquiring an additional 199,900 shares in the last quarter. SG Americas Securities LLC boosted its stake in Invitae by 90.7% during the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after acquiring an additional 43,717 shares in the last quarter. Finally, Green Alpha Advisors LLC lifted its stake in shares of Invitae by 138.4% in the fourth quarter. Green Alpha Advisors LLC now owns 452,585 shares of the medical research company’s stock valued at $284,000 after buying an additional 262,760 shares in the last quarter. 61.28% of the stock is owned by institutional investors.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.